← Leaderboards
G Appel
Columbia University Health Sciences
$385,820
Attributed
$385,820
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$385,820 · 1
By mechanism
M01$385,820 · 1
Top collaborators
No co-investigators on record.
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Robyn J Barst$2,557,256
- Kevan C Herold$39,325,259
- Mary Sano$40,764,266
- Kazuhiko Yamada$21,077,647
- Yaakov Stern$60,326,200
Others in their field
Top investigators on “Adrenal Disorder”
- Keri Hammel · The Emmes Company, Llc$31,953,742
- Jill M Goldstein · Massachusetts General Hospital$27,100,387
- John P Capitanio · University Of California Davis$25,742,389
- Janet T. Holbrook · Johns Hopkins University$21,179,006
- Joren C Madsen · Massachusetts General Hospital$14,944,310
- Rajita Sinha · Yale University$14,363,460
Research focus
Adrenal DisorderAminoguanidineClinical ResearchClinical TrialsDiabetes Mellitus TherapyDiabetic NephropathyDiabetic RetinopathyDrug Screening /EvaluationHuman SubjectHuman Therapy EvaluationKidney Disorder ChemotherapyPathologic ProcessPlacebos
Grant awards (5)
AMINOGUANIDINE IN DIABETIC PATIENTS WITH OVERT DIABETIC NEPHROPATHY$192,910
M01 · FY2002 · RR
AMINOGUANIDINE IN DIABETIC PATIENTS WITH OVERT DIABETIC NEPHROPATHY$192,910
M01 · FY2001 · RR
AMINOGUANIDINE IN DIABETIC PATIENTS WITH OVERT DIABETIC NEPHROPATHY$0
M01 · FY2001 · RR
AMINOGUANIDINE IN DIABETIC PATIENTS WITH OVERT DIABETIC NEPHROPATHY$0
M01 · FY2000 · RR
AMINOGUANIDINE IN DIABETIC PATIENTS WITH OVERT DIABETIC NEPHROPATHY$0
M01 · FY2000 · RR